In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, Fate Therapeutics Inc’s stock clocked out at $1.07, up 5.94% from its previous closing price of $1.01. In other words, the price has increased by $5.94 from its previous closing price. On the day, 2.1 million shares were traded.
Ratios:
To gain a deeper understanding of FATE’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.81 and its Current Ratio is at 8.81. In the meantime, Its Debt-to-Equity ratio is 0.29 whereas as Long-Term Debt/Eq ratio is at 0.27.
On June 17, 2024, Piper Sandler Upgraded its rating to Overweight which previously was Neutral and also upped its target price recommendation from $4 to $6.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 06 ’25 when Wolchko J Scott bought 113,178 shares for $0.93 per share.
Bressi Jerome Charles sold 5,980 shares of FATE for $9,269 on Jan 10 ’25. The insider now owns 270,203 shares after completing the transaction at $1.55 per share. On Jan 10 ’25, another insider, TAHL CINDY, who serves as the insider of the company, sold 5,654 shares for $1.55 each. As a result, the insider received 8,764 and left with 336,707 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 9.19 while its Price-to-Book (P/B) ratio in mrq is 0.43.
Stock Price History:
Over the past 52 weeks, FATE has reached a high of $5.92, while it has fallen to a 52-week low of $0.66. The 50-Day Moving Average of the stock is 5.55%, while the 200-Day Moving Average is calculated to be -50.40%.
Shares Statistics:
A total of 114.60M shares are outstanding, with a floating share count of 107.09M. Insiders hold about 9.70% of the company’s shares, while institutions hold 83.33% stake in the company.
Earnings Estimates
A detailed examination of Fate Therapeutics Inc (FATE) is currently in progress, with 10.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.32, with high estimates of -$0.23 and low estimates of -$0.35.
Analysts are recommending an EPS of between -$1.0 and -$1.38 for the fiscal current year, implying an average EPS of -$1.26. EPS for the following year is -$1.12, with 11.0 analysts recommending between -$0.73 and -$1.53.
Revenue Estimates
A total of 10 analysts have provided revenue estimates for FATE’s current fiscal year. The highest revenue estimate was $13.6M, while the lowest revenue estimate was $1.63M, resulting in an average revenue estimate of $5.2M. In the same quarter a year ago, actual revenue was $13.63M
